期刊
CURRENT OPINION IN GASTROENTEROLOGY
卷 30, 期 1, 页码 34-39出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MOG.0000000000000024
关键词
Clostridium difficile; donor feces infusion; fecal microbiota transplantation; inflammatory bowel syndrome; metabolic syndrome
资金
- Netherlands Organization for Health Research and Development
- Dutch Heart Foundation [170881001, 016096044, CVON 2012-IN CONTROL]
Purpose of reviewTo review the current evidence on fecal microbiota transplantations (FMTs) for recurrent Clostridium difficile infections (CDIs), metabolic syndrome and inflammatory bowel disease.Recent findingsRecently, a randomized trial confirmed the efficacy of this treatment strategy in patients with recurrent CDI. For other disorders, evidence is still limited. To date, studies have been performed to try and influence the course of metabolic syndrome and inflammatory bowel disease.SummaryThere is increasing interest in the role of altered microbiota in the development of a myriad of diseases. Together with new insights comes an interest in influencing this altered microbiota as a potential target for therapy. FMTs are effective against recurrent CDI, a disorder caused by disruption of the normal microbiota. Restoration of intestinal flora and thereby restoration of colonization resistance is thought to be the mechanism responsible for cure. With the developments in FMT and the extension of this treatment modality to both intestinal and extra-intestinal diseases, a new field of targeted therapy awaits. The ultimate goal is the development of powerful probiotic regimens that can replace FMT. Currently, FMT should only be given in a strict experimental setting for other conditions than CDI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据